BioCentury
ARTICLE | Clinical News

Genaera starts Phase IIb NSCLC trial

November 28, 2001 8:00 AM UTC

GENR began a U.S. Phase IIb trial of its squalamine angiogenesis inhibitor in combination with weekly chemotherapy in up to 90 patients with advanced non-small cell lung cancer (NSCLC). Patients will ...